ZymoGenetics and Merck Serono Initiate Second Phase 2/3 Clinical Study of Atacicept in Lupus
... a result of new information, future events or otherwise. ZymoGenetics, Inc. Susan W. Specht, MBA, 206-442-6592 Director, Corporate Communications or Michael Fitzpatrick, 206-442-6702 Associate Director, Corporate Communications ...
More...
... a result of new information, future events or otherwise. ZymoGenetics, Inc. Susan W. Specht, MBA, 206-442-6592 Director, Corporate Communications or Michael Fitzpatrick, 206-442-6702 Associate Director, Corporate Communications ...
More...